Research
Hormonal
The benefits of GLP-1R agonists may be enhanced by stimulating other receptors.
Combining GLP-1R agonists with other receptor agonists may enhance therapeutic outcomes.
StrongSupportsmedium confidence
It turned out that their benefit could be improved when they also stimulated the glucagon receptor (GCGR) and/or the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR).
Why this rating
The study discusses the potential for improved efficacy based on receptor interactions.
Source
Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart
Joachim Neumann et al. · Pharmaceutics · 2026
DOI 10.3390/pharmaceutics18040447
other
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →